2CV Stock Overview
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
ConvaTec Group PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£3.32 |
| 52 Week High | UK£3.44 |
| 52 Week Low | UK£2.24 |
| Beta | 0.57 |
| 1 Month Change | -0.60% |
| 3 Month Change | 17.73% |
| 1 Year Change | 36.07% |
| 3 Year Change | 39.50% |
| 5 Year Change | 114.19% |
| Change since IPO | 33.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2CV | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 1.2% | 1.7% | 1.7% |
| 1Y | 36.1% | -7.7% | 2.3% |
Return vs Industry: 2CV exceeded the German Medical Equipment industry which returned -9.5% over the past year.
Return vs Market: 2CV exceeded the German Market which returned 2.2% over the past year.
Price Volatility
| 2CV volatility | |
|---|---|
| 2CV Average Weekly Movement | 3.5% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2CV has not had significant price volatility in the past 3 months.
Volatility Over Time: 2CV's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 10,136 | Karim Bitar | www.convatecgroup.com |
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.
ConvaTec Group PLC Fundamentals Summary
| 2CV fundamental statistics | |
|---|---|
| Market cap | €6.79b |
| Earnings (TTM) | €121.75m |
| Revenue (TTM) | €2.00b |
55.8x
P/E Ratio3.4x
P/S RatioIs 2CV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2CV income statement (TTM) | |
|---|---|
| Revenue | US$2.14b |
| Cost of Revenue | US$938.20m |
| Gross Profit | US$1.20b |
| Other Expenses | US$1.07b |
| Earnings | US$130.30m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Jul 30, 2024
| Earnings per share (EPS) | 0.064 |
| Gross Margin | 56.21% |
| Net Profit Margin | 6.08% |
| Debt/Equity Ratio | 72.5% |
How did 2CV perform over the long term?
See historical performance and comparisonDividends
1.8%
Current Dividend Yield97%
Payout RatioDoes 2CV pay a reliable dividends?
See 2CV dividend history and benchmarks| ConvaTec Group dividend dates | |
|---|---|
| Ex Dividend Date | Apr 25 2024 |
| Dividend Pay Date | May 23 2024 |
| Days until Ex dividend | 1 day |
| Days until Dividend pay date | 27 days |
Does 2CV pay a reliable dividends?
See 2CV dividend history and benchmarks